GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Flexion Therapeutics Inc (NAS:FLXN) » Definitions » Price-to-Tangible-Book

Flexion Therapeutics (Flexion Therapeutics) Price-to-Tangible-Book : (As of May. 11, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Flexion Therapeutics Price-to-Tangible-Book?

As of today (2024-05-11), Flexion Therapeutics's share price is $9.12. Flexion Therapeutics's Tangible Book per Share of Sep. 2021 for the quarter that ended in Sep. 2021 was $-1.64. Hence, Flexion Therapeutics's Price to Tangible Book Ratio of today is .

The historical rank and industry rank for Flexion Therapeutics's Price-to-Tangible-Book or its related term are showing as below:

During the past 10 years, Flexion Therapeutics's highest Price to Tangible Book Ratio was 72.93. The lowest was 0.00. And the median was 3.85.

FLXN's Price-to-Tangible-Book is not ranked *
in the Drug Manufacturers industry.
Industry Median: 2.41
* Ranked among companies with meaningful Price-to-Tangible-Book only.

A closely related ratio is called PB Ratio. As of today, Flexion Therapeutics's share price is $9.12. Flexion Therapeutics's Book Value per Sharefor the quarter that ended in Sep. 2021 was $-1.64. Hence, Flexion Therapeutics's P/B Ratio of today is .


Flexion Therapeutics Price-to-Tangible-Book Historical Data

The historical data trend for Flexion Therapeutics's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Flexion Therapeutics Price-to-Tangible-Book Chart

Flexion Therapeutics Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Price-to-Tangible-Book
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.22 3.62 3.90 - -

Flexion Therapeutics Quarterly Data
Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21
Price-to-Tangible-Book Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Flexion Therapeutics's Price-to-Tangible-Book

For the Drug Manufacturers - Specialty & Generic subindustry, Flexion Therapeutics's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Flexion Therapeutics's Price-to-Tangible-Book Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Flexion Therapeutics's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Flexion Therapeutics's Price-to-Tangible-Book falls into.



Flexion Therapeutics Price-to-Tangible-Book Calculation

Flexion Therapeutics's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book=Share Price/Tangible Book per Share (Q: Sep. 2021 )
=9.12/-1.637
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.


Flexion Therapeutics Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Flexion Therapeutics's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.


Flexion Therapeutics (Flexion Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
10 Mall Road, Suite 301, Burlington, MA, USA, 01803
Flexion Therapeutics Inc is a United States-based specialty pharmaceutical company. The company focuses on the development and commercialization of novel, local therapies. The company specializes in the treatment of patients with musculoskeletal conditions beginning with osteoarthritis. The products offered by company are zilretta which is used for enhancing the clinical effect of intra-articular corticosteroid treatment.
Executives
Mark S. Levine officer: General Counsel 1601 TRAPELO ROAD, SUITE 284, WALTHAM MA 02451
Kerry Wentworth officer: Chief Regulatory Officer AGENUS INC., 3 FORBES ROAD, LEXINGTON MA 02421
Christina Willwerth officer: Chief Strategy Officer C/O FLEXION THERAPEUTICS, INC. 10 MALL ROAD, SUITE 301 BURLINGTON MA 01803
David Arkowitz officer: Chief Financial Officer C/O FLEXION THERAPEUTICS, INC., 10 MALL ROAD, SUITE 301, BURLINGTON MA 01803
Melissa Layman officer: Chief Commercial Officer C/O FLEXION THERAPEUTICS, INC. 10 MALL ROAD, STE. 301 BURLINGTON MA 01803
Scott Kelley officer: Chief Medical Officer C/O ASPECT MEDICAL SYSTEMS INC 141 NEEDHAM ST NEWTON MA 02464-1505
Elizabeth Kwo director C/O FLEXION THERAPEUTICS, INC., 10 MALL ROAD, SUITE 301, BURLINGTON MA 01803
Michael D. Clayman director, officer: President and CEO C/O FLEXION THERAPEUTICS, INC., 10 MALL ROAD, SUITE 301, BURLINGTON MA 01803
Alan Milinazzo director C/O ORTHOFIX INC, 10115 KINCEY AVENUE STE 250, HUNTERSVILLE NC 28078
Scott A Canute director FLEXION THERAPEUTICS, INC., 10 MALL ROAD, SUITE 301, BURLINGTON MA 01803
C Ann Merrifield director
Heath Lukatch director 326 BOLLAY DRIVE, GOLETA CA 93117
Samuel D Colella director, 10 percent owner ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Patrick J Mahaffy director C/O CLOVIS ONCOLOGY, INC., 5500 FLATIRON PARKWAY, SUITE 100, BOULDER CO 80301
Mark Stejbach director C/O TENGION, INC., 2900 POTSHOP LANE, SUITE 100, EAST NORRITON PA 19403

Flexion Therapeutics (Flexion Therapeutics) Headlines

From GuruFocus